PURA - Puration Announces First Foreign CBD Beverage Bottling Contract
December 12 2019 - 3:23PM
InvestorsHub Cannabis NewsWire
Dallas, TX -- December 12, 2019 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) today announced entering into a contract to begin
bottling EVERx CBD Sports Water in Europe. The company
recently announced acquiring a company to facilitate bottling in
Europe as part of an overall initiative to expand bottling capacity
world-wide. The company also recently European a distribution agreement in Europe
estimated to add $4 million in sales next year. Management
indicates that the potential of European distribution beyond the
initial $4 million projection warranted the establishment of a
local bottling capacity. The European market for CBD is projected
to reach nearly US
$17 billion by 2023.
The company has scheduled an update with more details on the
company’s recently announced 2020 expansion plan scheduled for next
week on Tuesday, December 17, 2019. PURA’s expansion is
intended to substantially increase PURA’s 2020 prospects beyond its
current $8 million revenue target. PURA has recently
reconfirmed its $4 million revenue target for 2019 and an $8
million revenue target for 2020. The CBD beverage market is
one of the fastest growing beverage sectors anticipated to reach
$1.4 billion by 2023.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024